Intranasal fentanyl for the treatment of breakthrough pain in cancer patients. A randomised, double-blind, placebo-controlled, cross-over confirmatory trial testing fentanyl and placebo in eight breakthrough pain episodes.

Trial Profile

Intranasal fentanyl for the treatment of breakthrough pain in cancer patients. A randomised, double-blind, placebo-controlled, cross-over confirmatory trial testing fentanyl and placebo in eight breakthrough pain episodes.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2012 Planned number of patients changed from 150 to 175 as reported by EudraCT.
    • 04 May 2012 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 17 Aug 2008 Secondary endpoint 'Additional treatment required rescue medication' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top